Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FARESTON vs DUAVEE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
FDA-approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Off-label: treatment of advanced breast cancer in premenopausal women in combination with ovarian suppression
Moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis
60 mg orally once daily.
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
Primarily hepatic via CYP3A4 and CYP1A2; undergoes glucuronidation; active metabolite N-desmethyltoremifene
Conjugated estrogens are primarily metabolized in the liver via phase II conjugation (sulfation and glucuronidation) by enzymes such as UGT1A1, UGT1A8, UGT1A9, UGT2B7, and SULT1A1. Bazedoxifene undergoes hepatic metabolism via glucuronidation by UGT1A1, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP involvement.
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
Toremifene is >99% bound to plasma proteins, primarily albumin.
Conjugated estrogens: extensive binding to albumin (approximately 80-85%). Bazedoxifene: highly bound (>99%) to albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution (Vd) is approximately 580 L (about 8 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Conjugated estrogens: Vd approximately 0.5-2 L/kg, indicating distribution into total body water and tissues. Bazedoxifene: Vd approximately 1.2 L/kg, suggesting extensive tissue distribution.
Oral bioavailability of toremifene is not precisely determined but is estimated to be nearly 100% based on absorption and first-pass metabolism studies.
Conjugated estrogens: oral bioavailability is approximately 30-50% due to first-pass metabolism. Bazedoxifene: absolute oral bioavailability is approximately 6% due to extensive first-pass glucuronidation.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Contraindicated in Child-Pugh class C; use with caution in class A or B without specific dose reduction guidelines.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh Class A or B; no specific dose adjustment established, but monitor closely.
Safety and efficacy not established; no recommended dose.
Not indicated for use in pediatric patients. Safety and efficacy have not been established.
No specific dose adjustment; monitor renal function and electrolyte balance.
No specific dose adjustment recommended. Higher risk of adverse events (e.g., thromboembolism, stroke) in women >65 years of age; use lowest effective dose for shortest duration.
None
Estrogen therapy increases the risk of endometrial cancer in women with a uterus. Concomitant use of a progestin or bazedoxifene is required to reduce this risk. Cardiovascular disorders: Estrogen-alone therapy may increase risk of stroke and DVT. Estrogen plus progestin therapy increases risk of MI, stroke, invasive breast cancer, pulmonary emboli, and DVT. DUAVEE is not approved for cardiovascular disease prevention. Breast cancer: Estrogen plus progestin therapy increases risk of invasive breast cancer. Probable dementia: Estrogen plus progestin therapy increases risk in women 65+.
QT interval prolongation,Hypercalcemia in patients with bone metastases,Endometrial hyperplasia/cancer risk,Thromboembolic events,Ocular toxicity (dose-dependent retinopathy),Tumor flare
Cardiovascular disorders (stroke, DVT, MI, pulmonary embolism),Malignant neoplasms (endometrial cancer, breast cancer),Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Exacerbation of asthma, diabetes, migraine, porphyria, SLE, hepatic hemangiomas,Retinal vascular thrombosis
Hypersensitivity to toremifene or any excipients,History of thromboembolic disease,Pre-existing endometrial hyperplasia,Patients with long QT syndrome or concurrent use of QT-prolonging drugs
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE),Active or past history of arterial thromboembolism (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hypersensitivity to any component,Pregnancy
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition, which can increase toremifene levels and risk of adverse effects. No other significant food interactions known. Take with or without food.
Grapefruit juice may increase estrogen levels; avoid large amounts. No other significant food interactions. Alcohol may increase risk of liver issues; limit intake.
Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: Potential for fetal hypothalamic-pituitary-gonadal axis disruption, ambiguous genitalia in female fetuses, and other adverse effects based on animal studies.
DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and delayed cognitive development. Bazedoxifene is a selective estrogen receptor modulator; animal studies show embryotoxicity and fetotoxicity at clinically relevant doses.
Not recommended during breastfeeding. Toremifene may be excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including hormonal disruption.
Contraindicated during breastfeeding. Estrogens and bazedoxifene are excreted in human milk; M/P ratio not reported. Estrogens may reduce milk production and quality. Potential for adverse effects in nursing infants.
No established dose adjustments; use contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered clearance) may require empirical dose reduction if used inadvertently, but no specific guidelines exist. Avoid use.
No dose adjustments applicable; do not use in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication.
FARESTON (toremifene) is a selective estrogen receptor modulator (SERM) used for metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors. Unlike tamoxifen, toremifene has a longer half-life (about 5 days) and may have a lower risk of thromboembolic events. Monitor liver function tests regularly due to potential hepatotoxicity. Prolongation of QT interval has been reported; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Use with caution in patients with endometrial hyperplasia or history of thromboembolic disease.
DUAVEE (conjugated estrogens/bazedoxifene) is indicated for moderate-to-severe vasomotor symptoms and osteoporosis prevention in postmenopausal women with a uterus. Avoid in women with intact uterus who are not on a progestin; bazedoxifene is the progestin component. Contraindicated in women with undiagnosed abnormal genital bleeding, known/suspected pregnancy, breast cancer, estrogen-dependent neoplasia, active DVT/PE, or history of these conditions. Monitor for thromboembolic events. Not for use in women with prior hysterectomy. Discontinue if jaundice or visual disturbances occur.
Take this medication exactly as prescribed, usually once daily with or without food.,You may experience hot flashes, nausea, or sweating; these are common and usually manageable.,Report any unusual vaginal bleeding, discharge, or pelvic pain to your doctor immediately.,Watch for signs of blood clots such as leg pain/swelling, sudden chest pain, or shortness of breath.,Avoid grapefruit and grapefruit juice while on this medication as they may increase side effects.,Use non-hormonal contraception if you are still able to become pregnant; toremifene can harm a fetus.,Do not stop or change your dose without consulting your healthcare provider.
Take DUAVEE once daily with or without food.,This medication is for postmenopausal women with a uterus; it contains both estrogen and a progestin-like drug to protect the uterine lining.,Do not use if you have any unexplained vaginal bleeding, are pregnant, have or have had breast cancer, blood clots, or liver disease.,Report promptly any signs of blood clots (leg pain/swelling, chest pain, sudden shortness of breath) or stroke (sudden headache, vision/speech changes).,DUAVEE may increase risk of gallbladder disease, dementia (if started after age 65), and endometrial hyperplasia if the progestin component fails.,Smoking while on DUAVEE increases risk of blood clots; avoid smoking.,DUAVEE does not prevent heart attack or stroke; in fact, it may increase cardiovascular risk, especially in older women.,Store at room temperature, away from moisture and heat.,If you miss a dose, take it as soon as possible; if almost time for the next dose, skip the missed dose and resume regular schedule. Do not double dose.,You will need regular medical check-ups including mammograms and pelvic exams.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FARESTON vs DUAVEE, answered by our medical review team.
FARESTON is a Selective Estrogen Receptor Modulator that works by Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.. DUAVEE is a Selective Estrogen Receptor Modulator/Estrogen Combination that works by DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FARESTON and DUAVEE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FARESTON is: 60 mg orally once daily.. The standard adult dose of DUAVEE is: One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FARESTON and DUAVEE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FARESTON is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: P. DUAVEE is classified as Category C. DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies includi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.